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We have studied the effects of D-threo-l-phenyl-2-decanoylamino-3-morpholino-l-propanol (D-PDMP) and its L- 
enantiomer on glycosphingolipids in cultured normal human kidney proximal tubular cells. We found that D-PDMP 
exerted a concentration-dependent reduction in the metabolic labelling and cellular levels of glucosylceramide 
(GlcCer), lactosylceramide (LacCer), and the globo-series glycosphingolipids, GbOse3Cer and GbOse4Cer. It also 
directly inhibited the activity of UDP-glucose:ceramide /31 ---> 4-glucosyltransferase (GlcT-1) and UDP-galactose: 
GlcCer /31 ---> 4 galactosyltransferase (GAIT-2). In contrast, L-PDMP had opposite effects on the metabolic labelling 
of GlcCer, LacCer, and GbOse3Cer. The levels of GlcCer and LacCer were increased, while the labelling and level 
of GbOse4Cer were strongly reduced. Purified GalT-2 from human kidney was inhibited by D-PDMP and 
stimulated by L-PDMR It appears likely that the different glycosphingolipid glycosyltransferases possess similar 
binding sites for the ceramide moiety, which are blocked by binding to D-PDMP and, in the case of GbOse4Cer 
synthase, by L-PDMP as well. The stimulatory effects of L-PDMP on GtcCer and LacCer synthases may be the 
result of binding to a modulatory site on the glycosyltransferases; in intact cells, the enzyme-analog complex may 
afford protection against the normal catabolic inactivation of the enzymes. 
Keywords: PDMP (1-phenyl-2-decanoylamino-3-morpholino-l-propanol), glucosylceramide, lactosylceramide, 
globotriaosylceramide, globotetraosylceramide, inhibition and stimulation by PDMP enantiomers 
Abbreviations: GalT-2, UDP-galactose:GlcCer /3-galactosyltransferase; GbOse3Cer , Galc~l ---> 4Gal/31 --9 GlcCer; 
GbOse4Cer, GalNAcl ---> 3Galc~l ---> 4Gal/31 ---> GlcCer; GlcCer, glucosylceramide; GlcT-1, UDP-glucose:ceramide 
/3-glucosyltransferase; GSLs, glycosphingolipids; LacCer, lactosylceramide; PDMP, threo-l-phenyl-2- 
decanoylamino-3-morpholino- 1 -propanol. 
Introduction 
Glycosphingolipids (GSLs) are complex sugar-containing 
sphingolipids. Recently, these compounds have drawn 
increased attention because of  their possible functional 
roles in cell proliferation, cell differentiation and pro- 
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grammed cell death [1-3]. GSLs are composed of  a 
sphingol (a long-chain sphingoid base), a fatty acid, and a 
simple or complex carbohydrate moiety. The hydrophobic 
moiety of  GSLs, ceramide, is composed of  the sphingol 
substituted at its amino group by a fatty acid in amide 
linkage. The sequential transfer of  carbohydrate moieties 
from nucleotide sugars to ceramide gives rise to GSLs [4]. 
For example, the transfer o f  glucose from UDP-glucose to 
ceramide gives rise to glucosylceramide (GlcCer), which 
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serves as the base for several hundred GSLs. The enzyme 
that catalyzes this transfer is termed GlcT-1. The enzyme 
that transfers galactose from UDP-galactose to GlcCer to 
produce tactosylceramide (LacCer) is termed GalT-2. Our 
laboratory has reported the purification of  GalT-2 from 
human kidney [5]. 
Both GlcCer and LacCer have been shown to induce 
proliferation in a variety of cells [1, 6]. For example, the 
effects of GlcCer on the proliferation of  a continuous cell 
line, MDCK, have been shown [6]. GlcCer enhanced 
epidermal proliferation [7] and, in intact mice, liver 
proliferation [8]. Previously we showed that, besides these 
two simple GSLs, other GSLs either moderately stimu- 
lated the proliferation of aortic smooth muscle cells or 
did not stimulate proliferation at all [I]. Most of the 
gangliosides investigated in our previous study did not 
stimulate the proliferation of cells, rather they caused a 
decrease in proliferation, possibly because they inhibit the 
biosynthesis of  GlcCer [9]. 
Other studies have shown the reverse effect: reduction 
of  cell growth and levels of GlcCer and LacCer by using 
a synthetic inhibitor of GSL biosynthesis [1, 6]. Proper- 
ties of the inhibitor, D-PDMP, have been reviewed 
recently [10, 11]. From kinetic data, it appears that the 
compound binds to a region near the UDP-glucose- 
binding site and to a second site that acts like an activity 
modulator. 
L-PDMP, on the other hand, stimulated the proliferation 
of  cultured aortic smooth muscle cells [I]. It was also 
found to increase the level of LacCer in B 16 melanoma 
cells [12, 13]. Taken together, these findings suggest that 
LacCer, GicCer or a derivative o f  these compounds is 
involved in the proliferation of  normal cells and of  cells 
participating in proliferative diseases, such as athero- 
sclerosis, cancer, and polycystic kidney disease [1, 14]. In 
this paper, we have used both enantiomeric forms of 
PDMP to investigate the biochemical mechanisms of 
action of  these ceramide analogs on the activities of 
GlcT-1 and GalT-2 in cultured human proximal tubular 
cells. 
Materials and methods 
Isotopes and chemicals 
D-[6-3H]galactose (sp. act. 60 Cimmol -I, UDP-[14C]glu - 
cose (sp. act. 9.25 Gbqmmol-1), and UDP-[14C]galactose 
(sp. act. 12.2 Gbqmmol -I) were from Amersham Corp. 
and silicic acid (UnisilR) was from Clarkson Co., 
Williamsport, PA. Initial samples of D- and L-PDMP 
were furnished by the two last authors of this paper; later 
work was done with the materials from Matreya, Inc., 
Pleasant Gap, PA. Organic solvents were from J. T. Baker 
except for tetrahydrofuran, which was fiom Eastman, and 
redistilled just prior to use. Liquiscint was from National 
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Diagnostics, Somerville, N J. All other chemicals used 
were from Sigma, St. Louis, MO. 
Cell culture 
Normal proximal tubule cells were prepared from human 
kidney. Cells (10 5) were seeded in plastic Petri dishes 
(8 cm diam.) in 10 ml of medium containing 10% fetal 
bovine serum. The medium was changed on the third day. 
On the sixth das; the medium was removed and fresh 
medium containing lipoprotein-deficient human serum 
(1 mg of protein per ml) plus D-PDMP or L-PDMP was 
added as described in the figures and legends. The 
lipoprotein-deficient serum was used because whole serum 
stimulates GSL synthesis. 
One set of  dishes was incubated with [3H]galactose 
(5 gCim1-1) for 24 h and harvested. These radiolabelled 
cells were used to investigate the incorporation of 
galactose into GSLs as described previously [15]. A 
second set of cells, incubated with or without D- or L- 
PDMP for 24h, was harvested in phosphate-buffered 
saline and centrifuged. The cell pellets were utilized for 
the measurements of GSLs levels following extraction, 
purification, perbenzoylation and high performance liquid 
chromatography [16]. The third set of  cells was harvested 
in cacodylate buffer (pH 6.8) as described [4], and the 
cell extracts were then utilized for the measurement of 
activity of GlcT-1 and GalT-2 after a 2-h incubation as 
described [17]. 
Three dishes were pooled for each analysis and at least 
nine dishes were used for each variable tested. The error 
bars in each figure represent the standard deviation of 
each group. 
Results 
Effects o f  D- and L-PDMP on the incorporation o f  
[3H]galactose into GSLs 
We found that D-PDMP exerted a concentration-dependent 
inhibition of the incorporation of [3It]galactose into 
GlcCer (Fig. 1A). The effect became noticeable at 5 gM 
inhibitor. D-PDMP also markedly reduced the incorpora- 
tion of [3H]galactose into LacCer, GbOse3Cer, and 
GbOse4Cer (Fig. 1B-D). The latter decreases can be 
attributed, in part at least, to depleted levels of their 
precursor, GlcCer. However the decreases were seen with 
2.5 glvI PDMR which did not affect GlcCer radioactivity, 
suggesting the possibility of direct influences of D-PDMP 
on the synthases that forrn the higher GSLs, such as GalT- 
2. 
In contrast, L-PDMP stimulated the incorporation of 
[3H]galactose into GlcCer, LacCer and globotriaosylcer- 
amide (Fig. 1A-C). L-PDMP at 5 -20gM stimulated 
the incorporation of [3H]galactose into GlcCer --50% 
compared to controls. The stimulations in the incorpora- 
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Figure 1. Effects of D-PDMP and L-PDMP on the incorporation of [3H]galactose into various glycosphingolipids in cultured normal human 
proximal tubular cells. Cells (105) were seeded in 8 cm plastic Petri dishes. After they reached confluence, the medium was replaced with 
fresh medium containing lipoprotein-deficient serum, [3H]galactose (5 gCiml-1), and D-PDMP or L-PDMP (0-20 gM). Incubation was 
continued for 24 h. Next, the cells were harvested, GSLs were isolated, and the incorporation of  [3H] into individual GSLs was measured 
after separation on HPTLC plates and scintillation spectrometry. The data are reported as cpm per mg protein. The controt specific 
activities were: (A) GlcCer, t50 _+ 15;-(B) LacCer, 810 _+ 75; (C) GbOse3Cer, 11,550 + 1,444; and (D) GbOse4Cer, 4, 102 -+ 450. The 
protein contents of the dishes in the three sets were 580 -+ 51 gg in the control dishes, 510 +_ 25 gg in the D-PDMP dishes, and 590 _+ 60 
in the L-PDMP dishes. Asterisks above graph columns here and in the following figm-es show values that are statistically different 
(p < 0.005) from the control values. 
tion of  [3HI into LacCer and GbOse3Cer were even 
greater, and dose-dependent (Fig. 1B, C). Thus the 
possibility is raised that L-PDMP stimulated the 
synthases forming LacCer and GbOse3Cer, in addition 
to GlcCer synthase. 
In a striking demonstration of  the specificity of  L- 
PDMP action, the compound produced a marked 
decrease in the incorporation of  [3H]galactose into 
GbOse4Cer, even at 2.5 ~tM (Fig. 1D). We may speculate 
that the L-isomer acts to directly inhibit the N- 
acetylgalactosaminyltransferase that forms GbOse4Cer. 
The same can be said for D-PDMt~ which also strongly 
inhibited the incorporation of  [3H]-Gal into GbOse4Cer, 
more so than into its precursor. 
Effects of  D-PDMP and L-PDMP on the cellular levels of  
GSLs 
D-PDMP produced marked decreases in the concentrations 
of  GtcCer, LacCer, GbOse3Cer, and GbOse4Cer. Such 
decreases in GlcCer and LacCer have previously been 
seen in a variety of  cell types and they are evidently due, 
in part at least, to depletion of  GlcCer stores by the direct 
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inhibitory action of  D-PDMP on GtcCer synthase. 
Presumably all the GSLs are in a dynamic state, under- 
going hydrolysis as well as synthesis; thus they decrease 
in concentration as the supply of GlcCer decreases. The 
decreases in GbOse3Cer and GbOse4Cer have not been 
reported before. The most remarkable effect of D-PDMP 
was on the cellular levels of GbOse3Cer, acting at 
concentrations <2.5 gM. This difference suggests that 
D-PDMP directly ~inhibits GbOse3Cer synthase. 
As might be expected from L-PDMP's effects on 
[3H]galactose incorporation into the GSLs (Fig. 1), the 
ceramide analogue markedly stimulated the cellular levels 
of GlcCer, LacCer and (to a small extent) GbOse3Cer, 








0 2.5 5.0 10 20 
Concentration (gM) 
Chatterjee et al. 
The cellular level of  GtcCer was increased approximately 
100% with 10 gM L-PDMR At higher concentrations, the 
levels of  GlcCer were decreased but still about 60% 
higher than the control value. At higher concentrations 
(20gM), the stimulatory actions of L-PDMP were 
lessened, suggesting the possibility that the compound 
acts at two sites, one stimulatory, the other inhibitory. 
Effects o f  L- and D-PDMP on the activity o f  GlcT-t and 
GatT-2 in celt extracts 
D-PDMP exerted a concentration-dependent inhibition of 
the specific activity of GlcT-1 in the crude extracts from 
normal cells (Fig. 3A). Distinct inhibition was seen at 
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Figure 2. Effects of D-PDMP and L-PDMP on the cellular levels of glycosphingolipids in cultuxed proximal tubular cells. The protocol 
described in Fig. 1 was followed except that the cells were incubated without [3H]galactose. Following incubation and harvesting, the GSLs 
were isolated and quantified by high performance liquid chromatography after perbenzoylation. The control values (nmol/mg protein) were: 
(A) GlcCer, 0.7 + 0.07; (B) LacCer, 0.3 -+ 0.03; (C) GbOse3Cer , 1.8 +- 0.15; (D) GbOse4Cer, 1.1 _+ 0.1. The protein contents of the three 
sets of dishes were 530 -_ 65 gg (controls, 485 -+ 45 gg (D-PDMP), and 554 + 70 ~tg (L-PDMP). 
Effects o f  D- and L-PDMP on glycolipid synthases 
30% of normal at 10 gM. This observation adds normal 
human kidney cells to the list of cells whose GlcT-1 is 
directly inhibited by PDMP. L-PDMP stimulated the 
activity of Glc%l in these cell extracts, in agreement 
with our observations o f  [3H] incorporation and cell 
GlcCer levels. 
We found that D-PDMP also decreased the activity of 
GaiT-2 in these enzyme preparations (Fig. 3B), although 
the effect was weaker than that seen with GlcT-1. On the 
other hand, L-PDMP markedly stimulated the activity of 
GalT-2, the effect being stronger than that seen with 
GlcT-1. The maximal stimulation, at 10btM, was 80% 
above the control activity. 
Effects olD- and L-PDMP on purified GalT-2 from human 
kidney 
Evidence that the above-described effects of PDMP on 
purified GalT-2 in broken cell preparations represented 
direct action on the enzyme (rather than indirect effects 
involving other cell components) was obtained by tests 
with purified GalT-2. We found that D-PDMP strongly 







inhibited GalT-2, even at a concentration of 1 btM 
(Fig. 3C). The use of higher D-PDMP concentrations did 
not lower the activity any further. 
In contrast, L-PDMP markedly stimulated the activity 
of GaiT-2 in the purified preparation. Here too the effect 
was visible at a low concentration. However, at higher 
concentrations (10-20 gM) L-PDMP acted as an inhibitor, 
again indicating opposing actions at two different enzyme 
sites (Fig. 3c). 
Discuss ion 
This study revealed several major findings. D-PDMR 
initially thought to inhibit only GlcCer synthase, was 
found to directly inhibit LacCer synthase (GAIT-2). 
Suggestive evidence was also found for a direct inhibitory 
action on the two globo-series synthases. These effects are 
in agreement with recent data from the Inokuchi 
laboratory [13], which found direct inhibition in B16 
melanoma cells of GlcT-1, GalT-2, and the sialyltransfer- 
ase that converts LacCer to ganglioside GM3. This rather 
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Figure 3. Effects of D-PDMP and L-PDMP on the activity, of 
UDP-glucose:Cer/31-->4 glucosyltransferase (GlcT-1) and UDP- 
galactose:GtcCer/31--+4 galactosyltransferase (GalT-2) activity in 
cultured human proximal tubular cells (A and B). The effects on 
purified GalT-2 from human kidney are shown in C. The control 
cell extract activities were: (A) 1.5 ± 0.1; (B) 2.5 ± 0.2; and 
(C) 251 _+ 20 nmol per mg protein/2 h. 
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general inhibitory action of D-PDMP is probably due to 
the presence of a similar binding site common to all these 
enzymes. At the present time we can only speculate that 
the ceramide-binding site, probably underwent little 
evolutionary mutation during the development of GSLs 
with more complex structures. The enzymes forming more 
complex GSLs, such as the ganglioside synthases, 
probably appeared later in evolutionary history, so their 
ceramide-binding regions may have mutated to regions 
that bind D-PDMP more weakly. The essential role of 
ceramide moiety in GalT-3 a galactosyltransferase that 
catalyzes the transfer of galactose form GM2 to GM1 has 
been reported [18]. This hypothesis raises the possibility 
that analogs of PDMP could be synthesized with more 
specific ability to inhibit the more complex synthases. 
Several new analogues have recently been described [19]; 
some of them are much more inhibitory against GlcT-1 
and it will be interesting to compare the enantiomeric 
forms against the higher glycosyltransferases. 
The stimulatory actions of L-PDMP reported here are 
consistent with the report that it increased the level of 
GIcT-1, GalT-2, and LacCer sialyltransferase in melanoma 
cells [13]. However those effects could be demonstrated 
only in growing cells, not in cell lysates, and it would 
appear that the phenomenon involved was inductive in 
nature. Culturing cells exposed to cycloheximide caused 
them to lose most of their GalT-2 activity, indicating that 
this enzyme normally undergoes rapid synthesis and 
inactivation. In the presence of L-PDMR however, the 
loss of enzyme was not as great. This may signify that L- 
PDMP binds to the enzyme, stabilizing it against the 
normal catabolic inactivation process. In the case of our 
purified GalT-2, the stimulation by L-PDMP was direct, 
not inductive. 
The especially strong reduction in synthesis of the 
globo-series GSLs reported in our study raises the 
possibility that a mixture of D- and L-PDMP would be 
particularly effective in blocking the binding of various 
pathogenic organisms [20,21]. These organisms must 
bind to globoside-bearing sites on human and porcine 
cells in order to produce their toxic actions. DL-PDMP 
has been shown to successfully block such binding 
between E. coli and human kidney and intestine cells in 
vitro [22]. Certain human tumours have also been shown 
to be enriched in globosides and it is possible that they 
are particularly sensitive to DL-PDMR 
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